Impact of patients' preexisting metabolic risk factors on the choice of antipsychotics by office-based physicians

Psychiatric Services

Volumn 62, Issue 12, 2011, Pages 1477-1484

  Li, Chenghui ^a   Mittal, Dinesh ^b,c   Owen, Richard R ^b,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE;

ADULT; ARTICLE; BODY MASS; DIABETES MELLITUS; FEMALE; HEALTH SURVEY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBESITY; PHYSICIAN; POLYPHARMACY; RISK FACTOR; UNDERWEIGHT;

EID: 84863270042     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.000882011     Document Type: Article

References (26)

1. Shekelle P, Maglione M, Bagley S, et al: Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics. Comparative Effectiveness Review no 6. Rockville, Md, Agency for Healthcare Research and Quality, Jan 2007
2. Domino ME, Swartz MS: Who are the new users of antipsychotic medications? Psychiatric Services 59:507-514, 2008
3. Leslie DL, Mohamed S, Rosenheck RA: Off-label use of antipsychotic medications in the Department of Veterans Affairs Health Care System. Psychiatric Services 60:1175-1181, 2009
4. Kuehn BM: Questionable antipsychotic prescribing remains common, despite serious risks. JAMA 303:1582-1584, 2010
5. IMS Drug Sale Report. Danbury, Conn, IMS, Apr 6, 2010 update. Available at www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top-Line- Data/Top%20Therapy%20Classes%20by%20U.S.Sales.pdf. Accessed Feb 11, 2011
6. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al: Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 27:596-601, 2004
7. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(suppl 1):1-93, 2005
8. Alison DB, Mentore JL, Heo M, et al: Antipsychotic- induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 156:1686-1696, 1999 (Pubitemid 29517559)
9. Czobor P, Volavka J, Sheitman B, et al: Antipsychotic- induced weight gain and therapeutic response: a differential association. Journal of Clinical Psychopharmacology 22:244-251, 2002 (Pubitemid 34546838)
10. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al: Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. Journal of Clinical Psychiatry 63:920-930, 2002 (Pubitemid 35231733)
11. NAMCS Micro-Data File Documentation. Hyattsville, Md, National Center for Health Statistics, 2006. Available at www.cdc.gov/nchs/ahcd/ahcd- questionnaires.htm#downloadabledocumentation. Accessed Feb 08, 2011
12. Nussbaum AM, Stroup TS: Paliperidone for treatment of schizophrenia. Schizophrenia Bulletin 34:419-422, 2008
13. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209-1223, 2005 (Pubitemid 41345943)
14. CDC Growth Chart. Atlanta, Ga, Centers for Disease Control and Prevention. Available at www.cdc.gov/healthyweight/assessing/bmi/childrens-bmi/ about-childrens-bmi.html
15. Stata (Release 9.2) Data Analysis and Statistical Software. College Station, Tex, StataCorp, 2007
16. Curkendall SM, Mo J, Glasser DB, et al: Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. Journal of Clinical Psychiatry 65:715-720, 2004
17. Dassori AM, Copeland LA, Zeber JE, et al: Factors in second-generation antipsychotic switching patterns in a national sample of older veterans with schizophrenia. Psychiatric Services 62:47-53, 2011
18. Marder SR, Essock SM, Miller AL, et al: Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161:1334-1349, 2004 (Pubitemid 38989085)
19. Kim S, Ivanova O, Abbasi FA, et al: Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. Journal of Clinical Psychopharmacology 27:365-368, 2007 (Pubitemid 47075507)
20. Faries DE, Ascher-Svanum H, Nyhuis AW, et al: Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psychiatry 9:54, 2009. DOI 10.1186/1471-244X-9-54
21. Hugenholtz GW, Heerdink ER, Meijer WE, et al: Reasons for switching between antipsychotics in daily clinical practice. Pharmacopsychiatry 38:122-124, 2005 (Pubitemid 40965964)
22. Ehret M, Goethe J, Lanosa M, et al: The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. Journal of Clinical Psychiatry 71:1286-1292, 2010
23. Khan AY, Macaluso M, McHale RJ, et al: The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review. Journal of Psychiatric Practice 16:289-296, 2010
24. Landry P, Dimitri E, Tessier S, et al. Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study. Journal of Clinical Psychopharmacology 28:348-349, 2008
25. Cutler AJ, Montgomery SA, Feifel D, et al: Extended-release quetiapine monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. Journal of Clinical Psychiatry 70:526-539, 2009
26. Correll CU, Frederickson AM, Kane JM, et al: Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophrenia Research 89:91-100, 2007 (Pubitemid 44881290)